DE3675408D1 - Phenylcarbamate. - Google Patents

Phenylcarbamate.

Info

Publication number
DE3675408D1
DE3675408D1 DE8686102812T DE3675408T DE3675408D1 DE 3675408 D1 DE3675408 D1 DE 3675408D1 DE 8686102812 T DE8686102812 T DE 8686102812T DE 3675408 T DE3675408 T DE 3675408T DE 3675408 D1 DE3675408 D1 DE 3675408D1
Authority
DE
Germany
Prior art keywords
sub
phenylcarbamate
pharmaceuticals
useful
phenyl carbamates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8686102812T
Other languages
German (de)
English (en)
Inventor
Rosin Marta Prof Weinstock
Michael Chorev
Zeev Tashma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proterra AG
Original Assignee
Proterra AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11055728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3675408(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Proterra AG filed Critical Proterra AG
Application granted granted Critical
Publication of DE3675408D1 publication Critical patent/DE3675408D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/14—Dithiocarbamic acids; Derivatives thereof
    • C07C333/30—Dithiocarbamic acids; Derivatives thereof having sulfur atoms of dithiocarbamic groups bound to other sulfur atoms
    • C07C333/32—Thiuramsulfides; Thiurampolysulfides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
DE8686102812T 1985-03-05 1986-03-04 Phenylcarbamate. Expired - Lifetime DE3675408D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL74497A IL74497A (en) 1985-03-05 1985-03-05 Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives

Publications (1)

Publication Number Publication Date
DE3675408D1 true DE3675408D1 (de) 1990-12-13

Family

ID=11055728

Family Applications (2)

Application Number Title Priority Date Filing Date
DE8686102812T Expired - Lifetime DE3675408D1 (de) 1985-03-05 1986-03-04 Phenylcarbamate.
DE1998175046 Pending DE19875046I1 (de) 1985-03-05 1986-03-04 Phenylcarbamate

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE1998175046 Pending DE19875046I1 (de) 1985-03-05 1986-03-04 Phenylcarbamate

Country Status (25)

Country Link
US (1) US4948807A (enExample)
EP (1) EP0193926B3 (enExample)
JP (1) JPS61225158A (enExample)
KR (1) KR940010764B1 (enExample)
AT (1) ATE58130T1 (enExample)
AU (1) AU595504B2 (enExample)
CA (1) CA1284501C (enExample)
CY (2) CY1748A (enExample)
DE (2) DE3675408D1 (enExample)
DK (1) DK172851B1 (enExample)
ES (1) ES8801193A1 (enExample)
FI (1) FI87197C (enExample)
GR (1) GR860586B (enExample)
HK (1) HK130293A (enExample)
HU (1) HU201297B (enExample)
IE (1) IE58838B1 (enExample)
IL (1) IL74497A (enExample)
LU (1) LU90312I2 (enExample)
MY (1) MY137602A (enExample)
NL (1) NL980031I2 (enExample)
NZ (1) NZ215348A (enExample)
PH (1) PH23325A (enExample)
PL (1) PL146301B1 (enExample)
PT (1) PT82127B (enExample)
ZA (1) ZA861653B (enExample)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH667001A5 (de) * 1985-09-03 1988-09-15 Hugo Degen Untermatratze.
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
US5091583A (en) * 1990-05-07 1992-02-25 Air Products And Chemicals, Inc. Tertiary amine catalysts for polurethanes
IT1271679B (it) * 1994-07-18 1997-06-04 Mediolanum Farmaceutici Srl Derivati del fenilcarbammato atti all'impiego come anticolinesterasici
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
US5965571A (en) * 1996-08-22 1999-10-12 New York University Cholinesterase inhibitors for treatment of Parkinson's disease
DE69732984T2 (de) 1996-12-18 2006-02-16 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
DE69725467T2 (de) * 1996-12-18 2004-07-22 Teva Pharmaceutical Industries Ltd. Phenylethylamin-derivate
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
EP0952826B1 (en) * 1997-01-17 2001-11-14 Takeda Chemical Industries, Ltd. Idebenone containing combination agent for treating alzheimer's disease
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
EP1133230A4 (en) * 1998-11-23 2004-05-26 Bonnie M Davis DOSAGE FORMULAS FOR ACETYLCHOLINESTERASE INHIBITORS
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
CN101519679B (zh) 2000-01-28 2013-11-13 Dsmip资产公司 通过在发酵罐中高密度培养真核微生物来增加含有多烯脂肪酸的脂质的产生
DK1311272T3 (da) * 2000-03-03 2007-02-26 Eisai R&D Man Co Ltd Hidtil ukendte fremgangsmåder hvor der anvendes cholinesteraseinhibitorer
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
CA2406383A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US7385076B2 (en) 2002-05-31 2008-06-10 Sun Pharmaceutical Industries Limited Process for the preparation of phenylcarbamates
EP2389937B1 (en) 2002-06-14 2018-08-15 Toyama Chemical Co., Ltd. Medicinal composition for improving brain function
CN100408556C (zh) * 2002-10-07 2008-08-06 加利福尼亚大学董事会 通过阻断花生四烯酰乙醇酰胺的水解调节焦虑
CZ20023555A3 (cs) * 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
DE10301851A1 (de) * 2003-01-17 2004-07-29 Lts Lohmann Therapie-Systeme Ag Verfahren zur medikamentösen Prophylaxe gegen Vergiftungen durch Cholinesterase-Hemmer, sowie hierfür geeignete Wirkstoffe und Arzneimittel
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
US7897639B2 (en) * 2003-10-21 2011-03-01 Colucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
ATE473967T1 (de) 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
GB0329284D0 (en) * 2003-12-18 2004-01-21 Avecia Ltd Process
GB2409453A (en) * 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
WO2005072713A2 (en) 2004-01-27 2005-08-11 The Feinstein Institute For Medical Research Cholinesterase inhibitors for treating inflammation
CA2555386A1 (en) * 2004-02-19 2005-09-01 Novartis Ag Use of cholinesterase inhibitors for treating vascular depression
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006050359A2 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
RU2393148C2 (ru) * 2004-11-08 2010-06-27 Эмкюр Фармасьютикалз Лимитед Способ получения (s)-3-[(1-диметиламино)этил]-фенил-n-этил-n-метил-карбамата
CA2590533C (en) * 2004-11-23 2010-09-07 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
BRPI0607017B8 (pt) 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
EP1956904B1 (en) * 2005-12-09 2017-04-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Low-dose ladostigil for the treatment of mild cognitive impairment
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
CA2650711A1 (en) * 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
DE602006015241D1 (de) * 2006-08-17 2010-08-12 Alembic Ltd Verbessertes verfahren zur herstellung von rivastigmin
WO2008037433A1 (en) 2006-09-29 2008-04-03 Synthon B.V. Process for making aminoalkylphenyl carbamates and intermediates therefor
CA2667553A1 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
EP2125709A2 (en) 2007-02-02 2009-12-02 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
EP1980552A3 (en) 2007-04-10 2008-10-29 Dr. Reddy's Laboratories Ltd. A process for the preparation of rivastigmine or a salt thereof
CN101707952B (zh) * 2007-04-16 2012-08-29 上海特化医药科技有限公司 一种制备利伐斯的明的方法及其中间体
US7884121B2 (en) 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
CA2693110A1 (en) * 2007-07-18 2009-01-22 Colucid Pharmaceuticals, Inc. Methods for promoting wakefulness
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
WO2010023535A1 (en) 2008-08-25 2010-03-04 Jubilant Organosys Limited A process for producing (s)-3-[(1-dimethylamino)ethyl] phenyl-n-ethyl-n-methyl-carbamate via novel intermediates
US8247405B2 (en) 2008-12-10 2012-08-21 Conopco, Inc. Skin lightening compositions with acetylcholinesterase inhibitors
CN101580482B (zh) * 2009-05-27 2014-04-23 沈阳药科大学 一种重酒石酸盐卡巴拉汀的制备方法和应用
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
CN102134206B (zh) * 2010-01-27 2013-11-20 上海京新生物医药有限公司 一种卡巴拉汀的制备方法
EA037187B1 (ru) * 2010-02-09 2021-02-17 Дзе Джонс Хопкинс Юниверсити Способ и композиция для лечения когнитивного расстройства
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
WO2011159910A2 (en) 2010-06-17 2011-12-22 Codexis, Inc. Biocatalysts and methods for the synthesis of (s)-3-(1-aminoethyl)-phenol
WO2012131699A1 (en) 2011-03-30 2012-10-04 Neon Laboratories Ltd. Process for preparation of highly pure 3-dimethylaminophenyl dimethylcarbamate
CN102786441B (zh) * 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
MX2014012374A (es) 2012-04-14 2015-04-17 Intra Cellular Therapies Inc Compuestos organicos.
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2015022418A1 (en) 2013-08-16 2015-02-19 Takeda Gmbh Treatment of cognitive impairment with pde4 inhibitor
AU2016268096B2 (en) 2015-05-22 2021-04-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1905990A (en) * 1931-01-02 1933-04-25 Hoffmann La Roche Disubstituted carbamic acid esters of phenols containing a basic constituent
US2208485A (en) * 1937-04-24 1940-07-16 Hoffmann La Roche Process for the manufacture of disubstituted carbamic acid esters of phenols containing a basic substituent
US2362508A (en) * 1940-12-06 1944-11-14 Merck & Co Inc Therapeutic substances
US2493710A (en) * 1947-03-21 1950-01-03 Hoffmann La Roche Carbamic acid esters
DE1037753B (de) * 1956-07-13 1958-08-28 Rohm & Haas Schaedlingsbekaempfungsmittel

Also Published As

Publication number Publication date
CY1748A (en) 1994-06-03
ES552627A0 (es) 1988-01-01
DK172851B1 (da) 1999-08-16
IE860558L (en) 1986-09-05
ES8801193A1 (es) 1988-01-01
JPH0255416B2 (enExample) 1990-11-27
CA1284501C (en) 1991-05-28
DK99186A (da) 1986-09-06
HUT41718A (en) 1987-05-28
IL74497A0 (en) 1985-06-30
DK99186D0 (da) 1986-03-04
KR860007207A (ko) 1986-10-08
PT82127B (pt) 1988-07-01
CY2004004I1 (el) 2009-11-04
EP0193926B1 (en) 1990-11-07
AU5428486A (en) 1986-09-11
NL980031I2 (nl) 1999-03-01
FI87197C (fi) 1992-12-10
JPS61225158A (ja) 1986-10-06
NZ215348A (en) 1990-04-26
HK130293A (en) 1993-12-03
PH23325A (en) 1989-07-14
IE58838B1 (en) 1993-11-17
ZA861653B (en) 1987-10-28
ATE58130T1 (de) 1990-11-15
IL74497A (en) 1990-02-09
NL980031I1 (nl) 1999-01-04
KR940010764B1 (ko) 1994-11-11
FI87197B (fi) 1992-08-31
DE19875046I1 (de) 2003-09-04
CY2004004I2 (el) 2009-11-04
PL146301B1 (en) 1989-01-31
EP0193926B3 (en) 2010-04-28
FI860914L (fi) 1986-09-06
EP0193926A3 (en) 1987-05-13
EP0193926A2 (en) 1986-09-10
FI860914A0 (fi) 1986-03-04
US4948807A (en) 1990-08-14
LU90312I2 (fr) 1999-01-06
MY137602A (en) 2009-02-27
GR860586B (en) 1986-07-07
PT82127A (en) 1986-04-01
HU201297B (en) 1990-10-28
AU595504B2 (en) 1990-04-05

Similar Documents

Publication Publication Date Title
DE3675408D1 (de) Phenylcarbamate.
FI872335A0 (fi) Bioreaktor.
DE3583779D1 (de) Gelzusammensetzungen von liposomen.
DE3681468D1 (de) Staubfreie koernige enzymzusammensetzung.
FI852755A7 (fi) Aminofenoliyhdisteet.
ATE38211T1 (de) Herstellung von zeolith-l.
DE3770889D1 (de) Herstellung von kubischem bornitrid.
DE3671902D1 (de) Haertbare zusammensetzung.
DE3586224D1 (de) 3-carbonyl-1-aminoalkyl-1h-indole, verwendbar als analgetika und ihre herstellung.
DE3382074D1 (de) Herstellung von hydroxyarylaldehyden.
FI870271A0 (fi) Sjaelvsmoerjande friktionsminskande sammansaettning.
IT8521212A0 (it) Composizioni covulcanizzabili di fluoroelastomeri.
FI850483A0 (fi) Saett och utrustning vid kontinuerlig cellulosakokning.
DE3581238D1 (de) Mikrobiologische herstellung von l-phenylalanin.
DE3764919D1 (de) Haertbare zusammensetzung.
DE3582003D1 (de) Herstellung von glycolmonoestern.
DE3670063D1 (de) Herstellung von thioantimonaten.
DE3650009D1 (de) Härtbare Zusammensetzung.
IT8720012A0 (it) Composizione anticorrosione.
DE3676116D1 (de) Herstellung von azetidin-derivaten.
FI890885L (fi) Foerfarande foer framstaellning av n-(s-3-alkylheptanoyl)-d-gamma-glutamyl-glycyl-d-alanin och i foerfarandet anvaendbara mellanprodukter och deras framstaellning.
SU1162191A1 (ru) 1,1-Этилиденди-(5-бром-2-фуроиламин), проявляющий противовоспалительную активность
DE3762851D1 (de) Herstellung von spirobiindanbisphenolbischloroformiat-zusammensetzungen.
SU1489139A1 (ru) 3-Изобутил-1-(4-тиоцианатофенил)-5-фенил-Δ-пиразолин, проявляющий противовоспалительную активность
ES280924Y (es) Cocina-barbacoa, portatil

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
V448 Application of spc

Free format text: PRODUCT NAME: RIVASTIGMIN (EXELON); REGISTRATION NO/DATE: EU/1/98/066/001 - EU/1/98/066/012; 19980512

Spc suppl protection certif: 198 75 046

Filing date: 19981112

V457 Spc granted

Free format text: PRODUCT NAME: RIVASTIGMIN (EXELON); REGISTRATION NO/DATE: EU/1/98/066/001 - EU/1/98/066/012; 19980512

Spc suppl protection certif: 198 75 046

Filing date: 19981112

V464 Spc expired

Free format text: PRODUCT NAME: RIVASTIGMIN (EXELON); REGISTRATION NO/DATE: EU/1/98/066/001 - EU/1/98/066/012; 19980512

Spc suppl protection certif: 198 75 046

Filing date: 19981112

R071 Expiry of right

Free format text: PRODUCT NAME: RIVASTIGMIN (EXELON); NAT. REGISTRATION NO/DATE: EU/1/98/066/001-012 19980512; FIRST REGISTRATION: CH/LI 5427501-06 19970731

Spc suppl protection certif: 19875046

Filing date: 19981112

Expiry date: 20060305

Extension date: 20110304

Effective date: 20110305